Key Highlights
- 0.19 is the loss per share in USD implied by the consensus EPS estimate of -0.19 for Neumora Therapeutics, Inc. (NASDAQ:NMRA), which reports third quarter 2026 results before the market opens on November 13, 2026.
- 43.1 million USD was the second quarter 2026 net loss, or USD 0.23 per share, versus USD 52.7 million, or USD 0.33 per share, in the second quarter of 2025, as research spending fell to USD 29.3 million.
- 116.8 million USD was the cash balance at June 30, 2026, down from USD 182.5 million at December 31, 2025, and management expects it to fund the operating plan into the third quarter of 2027.
- 88.87 million USD is the market Capitalization per the screener snapshot, below USD 100 million, while data from NMRA-511 and NMRA-898 studies are expected in the fourth quarter and second half of 2026.
What Investors Expect From Neumora Therapeutics, Inc. (NASDAQ:NMRA) on November 13, 2026
Per the screener snapshot, Neumora Therapeutics, Inc. reports third quarter 2026 results on November 13, 2026, before the market opens, with a consensus EPS estimate of -0.19 and a market capitalization of USD 88.87 million. The estimate is narrower than the second quarter loss of USD 0.23 per share, which implies further cost discipline. A prior-year third quarter comparison was not found in published coverage, and the call time was not detailed in the snapshot.
The Rationale: Last Reported Quarter and Management Outlook for Neumora Therapeutics, Inc. (NASDAQ:NMRA)
In the second quarter of 2026, Research and Development expense was USD 29.3 million versus USD 38.7 million, and general and administrative expense was USD 12.9 million versus USD 15.3 million. Six-month net loss was USD 96.5 million versus USD 120.7 million, or USD 0.53 per share. Joshua Pinto became president and chief executive officer, Paul Berns moved to Executive Chair, and Doron Sagman was named chief medical officer. Management plans an NMRA-215 IND submission in the fourth quarter of 2026, NMRA-511 data in the fourth quarter, an Alzheimer's agitation Phase 2 start by the end of 2026, and NMRA-898 data in the second half of 2026.
Valuation, Liquidity and Risks for Neumora Therapeutics, Inc. (NASDAQ:NMRA)
Cash fell by USD 65.7 million in six months (calculated), and the second quarter net loss was about 18% smaller than a year earlier (calculated). Weighted-average shares were 185.2 million versus 161.7 million. Cash of USD 116.8 million exceeds the snapshot market capitalization of USD 88.87 million (calculated gap of USD 27.9 million). The company has no product revenue. Risks include early-stage trial outcomes, financing needs after the third quarter of 2027, dilution and Leadership transition. At a Market Value below USD 100 million, small-cap stocks can be volatile and illiquid.
Where Things Stand
Where things stand: Neumora Therapeutics, Inc. (NASDAQ:NMRA) reports with a consensus EPS estimate of -0.19, a snapshot market capitalization of USD 88.87 million and USD 116.8 million of cash at June 30, 2026. Management lowered spending in the first half, with six-month research expense of USD 67.9 million versus USD 90.9 million, and expects cash to last into the third quarter of 2027. Pipeline updates on NMRA-215, NMRA-511 and NMRA-898 are guided to the fourth quarter and second half of 2026, so timing commentary is likely to matter. This is information only and not Investment advice.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...